This document provides information about the IBC Oncology Asia conference happening from November 25-28, 2014 in Singapore. The conference will focus on clinical development and market access strategies for oncology drugs in Asia. It will feature speakers from pharmaceutical companies discussing topics like market trends, developing competitive pipelines, biosimilars, clinical trials, understanding oncologists, market access strategies, pricing and reimbursement. There will also be pre and post-conference workshops on oncology clinical trials, biosimilars, and pricing and reimbursement models. The conference aims to help attendees learn how to expedite oncology drug development and successfully access cancer drug markets in Asia.

1. IBC
LIFE SCIENCES
Asia’s only strategic oncology conference focusing on
clinical development and market access
ASIA
Expediting Development and Improving Market Access
25 - 28 November 2014 | PARKROYAL on Beach Road, Singapore
Hear from Industry Leaders on Timely Topics Including:
Market Trends and Drivers
in the Region
James Garner
Head Unit Development Operations Asia R&D
Sanofi, Singapore
Produced by: Media Partners: International Marketing Partner:
Life
Sciences
www.oncologyasia.com
What You Need to Know When
Marketing Oncology Drugs
Dr Paul Cornes
Clinical Oncologist
Bristol Oncology Centre
United Kingdom
mABs and Biosimilars in
Oncology
Li-Chung Huang
Chief Quality Officer
Henlius Biopharmaceuticals USA/China
Developing Competitive
Pipelines & New Collaborative
Research Models
Jin-San Yoo
President and CEO
PharmAbcine, Korea
Successful Market Access
Strategies for Oncology Drugs
Sameer Agarwal
Senior Vice President,
Business Center Strategic Marketing
Fresenius Kabi Deutschland GmbH Germany
Clinical Engagement for
Successful Oncology Products
Dr Anish Desai
Director Medical & Clinical Affairs
Johnson & Johnson, India
Pre-Conference Workshop
25 November 2014
Oncology Clinical Trials
Post-Conference Workshop
28 November 2014
Pricing and Reimbursement
Models for Oncology Products
mAbs and Biosimilars
A
B
C
Oncology Clinical Trials
in Asia
Prof Alex Matter
CEO
Experimental Therapeutics Centre, A*Star
Singapore

2. 26 November 2014
CONFERENCE
DAY ONE WEDNESDAY
8.00 Registration & Morning Coffee
8.55 Welcome from IBC Asia & Speed Networking
9:05 Chairman’s Opening Remarks
Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre,
United Kindgom
TRENDS AND MARKET OVERVIEW
9:10 Market Trends and Drivers in the Region
• Outlook and opportunities for regional and global players
• The evolving landscape of the industry
• Demographics and healthcare trends in the region
• Market share, segmentation, oncology main players and
new players
James Garner, Head Unit Development Operations, Asia R&D,
Sanofi, Singapore
9:50 Developing Competitive Pipelines, Drug Discovery
Platforms and New Collaborative Research Models
• Expanding global business opportunities through
collaboration
• Updates on progress of recent licensing deal
• Evaluating the best time to partner or outsource
• Choosing the right company to partner with to support
business strategy
Jin-San Yoo, President and CEO, PharmAbcine, Korea
10:30 Morning Networking and Refreshment Break
NEXT GENERATION ONCOLOGY
PRODUCTS
11:00 mABs and Biosimilars in Oncology
• Current status of biosimilar development in oncology
• Effective monoclonal antibody development program in
oncology
• Lessons learned in quality, compliance and regulatory
approvals
• Key successful factors in developing and marketing
biosimilars in oncology
Li-Chung Huang, Chief Quality Officer, Henlius
Biopharmaceuticals, USA/China
Liver mABs
11:40 Addressing the Oncology NCE Bottleneck
• Taking an oncology drug from bench to clinical
• Less is More: Regulatory strategy of a liver cancer drug
• How the right drug delivery system can help
• Development strategy with global business opportunity
Dr Yunlong Tseng, Vice President, TLC Bio, Taiwan
Cancer
12:20 Networking Lunch
13:30 Roundtable Discussions:
• Clinical Development
Melvin Toh, Vice President Pharmaceutical Development,
CK Life Sciences, Hong Kong
• Early R&D
Dr Paul Cornes, Consultant Clinical Oncologist,
Bristol Oncology Centre
• Market Access
Salman Bokhari, Managing Director, Sidrapex, Singapore
ADVANCING CLINICAL DEVELOPMENT
14:30 Oncology Clinical Trials in Asia
Prof Alex Matter, CEO, Experimental Therapeutics Centre,
A*Star, Singapore
15:10 Afternoon Networking and Refreshment Break
15:40 Developing a Cost Effective Clinical Management
Strategy
• Streamlining clinical trial design to optimize operations
• Selecting the right investigators and sites to achieve
optimal outcomes in competitive oncology clinical
development
• Effectively managing multi-territory clinical trials sites to
expedite oncology drug development
Pei Yin Tan, Associate Director, Asia Clinical Operations,
Eisai Clinical Research, Singapore
16:10 Industry Academia Partnership For Enhancing
Professional Development in Clinical Oncology
• Does clinical development also pivot around professional
development ?
• Clinical oncology – broad professional development
themes
• Industry academia partnership – issues and challenges
• Successful partnerships – proposed approach and
solutions
Dr Aamir Shaikh, Founder, Assansa, India
16:50 Managing Asia Pacific Oncology Clinical Trials
• Advantages and challenges of clinical trials in the region
• New clinical trial requirements and their impact on
oncology drugs
• Strategies for success in clinical trials in Asia Pacific
• Global clinical trial strategies: aligning sites for global
submissions
Moderator:
Dr Paul Cornes, Consultant Clinical Oncologist,
Bristol Oncology Centre, United Kingdom
Panelists:
Melvin Toh, Vice President Pharmaceutical Development,
CK Life Sciences
Pei Yin Tan, Associate Director, Asia Clinical Operations,
Eisai Clinical Research, Singapore
Dr Anish Desai, Director Medical & Clinical Affairs,
Johnson & Johnson, India
PANEL DISCUSSION
17:35 Chairman’s Summary of the Day and
End of Conference Day One
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.oncologyasia.com

3. 27 November 2014 CONFERENCE
DAY TWO THURSDAY
9:00 Chairman’s Recap of Day One
Melvin Toh, Vice President Pharmaceutical Development,
CK Life Sciences, Hong Kong
UNDERSTANDING ONCOLOGISTS
AND PRESCRIBER BEHAVIOURS
9:10 Learning from Oncologists
• Our expectations from the pharma industry
• How we prefer to be engaged
• Our biggest challenge when interfacing with pharma
representatives
• Advice to the industry
Prof Roel Tolentino, Immediate Past President,
Philippine Society of Oncology
9:50 What You Need to Know When Marketing Oncology Drugs
• Facing the reality of corruption in medicine
• Impact of corruption on even the most ethical pharma
company
• How does a company work with the expectation of bribes
and extortion?
• Options and alternatives
Dr Paul Cornes, Consultant Clinical Oncologist,
Bristol Oncology Centre, United Kingdom
10:30 Morning Networking and Refreshment Break
11:00 Clinical Engagement for Successful Oncology Products
• Addressing the user concern on safety and driving change
in prescriptions
• Effectively engaging stakeholders to communicate
product value
• Publications, trainings and seminars to further educate
clinicians
• Lessons learned from the region
Dr Anish Desai, Director Medical & Clinical Affairs,
Johnson & Johnson, India
Medical
Device
MARKET ACCESS
11:40 Successful Market Access Strategies for Oncology Drugs
• Drivers of success for the oncology business
• Understanding the impact of changing healthcare markets
on oncology products
• Market dynamics and strategies to suitably address the
challenges
• Key criteria to consider for success in marketing
Sameer Agarwal, Senior Vice President, Business Center
Strategic Marketing, Fresenius Kabi Deutschland GmbH,
Germany
12:20 Networking Lunch
14:00 Role of Companion Diagnostics in Oncology
Market Access
• Impact of companion diagnostics in the marketing of
oncology drugs
• Current challenges in development
• Driving the marketing of the products
• Health economics and patient selection
Dr Bhuwnesh Agrawal, Chief Medical Officer,
Vela Diagnostics, Singapore
Companion
Diagnostocs
14:40 Preparing to Launch Oncology Drugs
• Growth trends in the region
• Early introduction into market
• Effective marketing strategies
• Do’s and dont’s when launching
Kok Leong Chan, Product Manager, Cancer Care Unit (CCU),
Roche, Malaysia
Gastrointestinal &
Breast Cancer
15:20 Afternoon Networking and Refreshment Break
15:50 What Works in Asia: Successfully Bringing Oncology
Drugs to Market
• What makes the region different
• Impact of demographics and culture in successful business
• Key factors to consider when choosing distribution
channels
• Final word on successful marketing
Vikram Shetty, Regional Medical Adviser, Takeda, Singapore
PRICING AND REIMBURSEMENT
16:30 Pricing and Reimbursement Models for Oncology
Products
• Pricing strategies in emerging markets
• Lessons learned from established markets
• Global challenges and strategies to address these
Dr Aamir Shaikh, Founder, Assansa, India
17:10 End of Oncology Asia
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.oncologyasia.com

4. WORKSHOPS
Pre-Conference Workshop A 25 November 2014 9:00am - 4:30pm
Oncology Clinical Trials
This workshop presents strategies and case studies of innovative
approaches, to help you understand what works and doesn’t work
in shortening drug development & regulatory timelines to make
new cancer drugs available to Asian patients faster.
Hear about:
Regulatory strategies, e.g. Pre-IND consultation, Fast Track, Priority
Review, Accelerated Approval, Special Review (SFDA)
About Your Workshop Leaders:
The impact of study design; innovative oncology trial designs and
development strategies, e.g. adaptive trials, use of biomarkers &
surrogate endpoints in oncology clinical trials
The promise of Asia to support more early phase oncology trials
The challenges of patient enrolment in oncology trials; Working
with service providers to improve patient recruitment in oncology
clinical trials
Operational strategies to overcome practical challenges in
oncology trials in Asia
The latest partnership models between sponsors and CROs for
oncology trials
Melvin Toh, Vice President Pharmaceutical Development, CK Life Sciences
Dr. Toh is Vice President, Pharmaceutical Development, at CK Life Sciences. CK Life Sciences pharmaceutical operations include Polynoma (US),
Wex Pharmaceuticals (Canada) and Renascence Therapeutics (Hong Kong).
Dr. Toh has a medical degree from the National University of Singapore and a MSc degree from the University of London. He has held various
management/ scientific positions in Asia and the USA, including Director of Clinical Pharmacology in Oncology Development at Pfizer Global R&D
based in San Diego, where he headed a team of scientists working on the clinical development of new cancer drugs. He was also previously Head/Medical
Director of the Pfizer Clinical Research Unit at the Singapore General Hospital.
Dr Paul Cornes, Consultant Clinical Oncologist, Bristol Oncology Centre, UK
Paul has been a NHS cancer clinical trial lead and has lectured on the biennial London TPI course on clinical trial designs and on improving the
effectiveness of clinical trials. He is part of the Wolfson Institute Cochrane Group at Bath and the Clinical Outcomes Group.
Post-Conference Workshop B 28 November 2014 9:00 am - 12:00 noon
Pricing and Reimbursement Models for Oncology Products
This workshop will discuss patients' perspectives of their willingness
to pay for oncology drugs, the search for novel reimbursement
models, and pricing strategies in emerging markets
Outline:
Review papers on willingness to pay for better care in Japan and
Korea
Solutions to impending cost-crisis
Led by:
Comparative effectiveness research
A look at key markets in and around the region:
• India plans a network of taxpayer funded centres based on
generics/biosimilars only
• Korea has highest co-pays in OECD developed nations
• US - social support to increase access
• UK - pay for success deals
• China - across the board demands for a price reduction
Dr Paul Cornes, Consultant Clinical Oncologist, Bristol Oncology Centre, UK
Aside from being a NHS cancer clinical trial lead and lecturer on clinical trial designs and on improving the effectiveness of clinical trials, Paul
helped to organise the Cambridge Blue-Sky Future Cancer meeting with the Centre for the Study of Financial Innovation. He encourages physicians
that health economics is to be embraced as part of routine medical practice. He was involved in the United Kingdom Health Technology Assessment
of Erythropoietins for cancer at NICE and has taught clinical and cost effective care to physicians, pharmacists and nurses in the European Union,
in the USA, in the Middle East, Asia and Russia.
Post-Conference Workshop C 28 November 2014 1:30 pm - 4:30 pm
mAbs and Biosimilars
Challenges in cancer treatment
Current status of biosimilar development in oncology
About Your Workshop Leader:
Developing cost-effective R&D programs for cancer therapeutics
by adopting new technology and Lean Six Sigma
Balancing pre-clinical studies and clinical studies
Successful marketing of biosimilars and biobetters in oncology
Li-Chung Huang, Chief Quality Officer, Henlius Biopharmacuetical, USA/China
Mr. Huang is an executive with 20 years of experience in biotech industry. He was previously worked with Bayer, Centocor, Imclone and Chempartner.
He previously served as the Chair of Philadelphia Section for the American Society for Quality (ASQ) and the Chair of Mid-Atlantic Biomedical and
Pharmaceutical Discussion Group. Throughout a career in biotech industry from scientist/engineer to executive in diverse fields of development,
analytical support, tech transfer, validation, manufacturing, quality control, compliance and supply chain, he has been recognized for the ability
to build and lead cross-functional teams and was awarded ten plus awards from the biotech industry and quality community.
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.oncologyasia.com

5. LIFE SCIENCES Asia’s only strategic oncology conference focusing on
clinical development and market access
ASIA
Expediting Development and Improving Market Access
25 - 28 November 2014 | PARKROYAL on Beach Road, Singapore
Cancer is the fastest growing healthcare priority within the worldwide pharmaceutical industry. The global
oncology market is expected to reach $150B with China’s market alone valued to be about $50 Billion by 2020,
growing at a rate of 20% per year.
(PharmaAsia October 2013)
The search for ‘the’ cancer blockbuster drug is still on and pharma
companies still need to create an effective strategy to access
the market.
Why You
Should Attend
Identify new trends and opportunities in
development and commercialization in Asia
Learn from in-depth case studies on
clinical development and successful market
access for oncology products
Gain insights from industry speakers
from global and regional
JOB TITLES
■ Head of Oncology 30%
■ Clinical 30%
■ Manufacturing 10%
■ Sales & Marketing 10%
■ R&D 10%
■ Others 10%
IBC
Oncology Asia is the first strategy conference that focuses
on the development and effective market access of cancer
drugs in the region. This is the meeting to learn how to
expedite oncology clinical development and break
through established and emerging markets in Asia.
pharma/biotech
Who Should Attend
BY INDUSTRIES
■ Big Pharma 50%
■ CROS 12%
■ Biotechs 10%
■ Medical Device & Diagnostics 5%
■ Generics Companies 5%
■ Research Institutes 5%
■ CRAMS/CMOs 5%
■ Finance / VC 5%
■ Others 3%
BY COUNTRIES
■ Singapore 30%
■ Malaysia 10%
■ Rest of SEA 10%
■ Japan 5%
■ Hong Kong 8%
■ China 15%
■ Taiwan 2%
■ USA 10%
■ Rest of the World 10%
SPONSORSHIP OPPORTUNITIES
Raise awareness for your services available to Pharmaceutical
companies in Asia.
• Do you find difficulty in reaching senior decision makers and
successfully stimulating interest for your services?
• Are you trying to raise awareness of the value of your company’s
expertise and services?
• Or are you finding it difficult to differentiate your company from
competition?
Perhaps what you need is a branding opportunity at this event!
Increase your reach through our extensive marketing campaign,
targeted at your qualified business audience.
For information about placing your brand & profile top-of-mind to
key buyers, contact Yvonne Leong, Business Development Manager
on Tel: + 65 6508 2489 or Email: yvonne.leong@ibcasia.com.sg
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.oncologyasia.com

6. Early Bird Rate
Register & pay on or
before 12 Sep 2014
Special Rate
Register & pay on or
before 10 Oct 2014
Register 3 Delegates & the
4th Attends for FREE!
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
10 Oct 2014
FEE PER DELEGATE
❑ 4 Day Pass: 2 Day Conference + All Workshops SGD 3,895 SGD 4,095 SGD 4,295 SGD 3,795
❑ 3.5 Day Pass: 2 Day Conference +
Workshops ❑ A + ❑ B or ❑ C
❑ 3 Day Pass: 2 Day Conference +
SGD 3,595 SGD 3,795 SGD 3,995 SGD 3,495
SGD 3,295 SGD 3,495 SGD 3,695 SGD 3,195
Workshops ❑ A or ❑ B + ❑ C
❑ 2.5 Day Pass: 2 Day Conference + SGD 2,995 SGD 3,195 SGD 3,395 SGD 2,895
Workshops ❑ B or ❑ C
❑ 2 Day Pass: 2 Day Conference Only SGD 2,595 SGD 2,795 SGD 2,995 SGD 2,495
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.
Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• A 7% Goods & Services Tax (GST) is applicable to all Singapore based companies for Singapore Venue.
FREE
MAIL the attached registration
form with your cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business
Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164
GROUP
DISCOUNT
This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
ONCOLOGY ASIA
Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Scan the QR Code with your
smartphone and register today
Customer Service Hotline
+65 6508 2401
Web
www.oncologyasia.com
HOTEL INFORMATION
PARKROYAL on Beach Road
7500 Beach Road, Singapore 199591
Hotel mainline: +65 6505 5666
Contact Person: Teo Hui Ling
Tel: +65 6505 5696
Email: teo.huiling@parkroyalhotels.com
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
Should you be unable to attend, a substitute delegate is
welcome at no extra charge. Cancellations must be received in
writing at least 10 business days before the start of the event,
to receive a refund less 10% processing fee per registration.
The company regrets that no refund will be made available for
cancellation notifications received less than 10 business days
before the event.
IMPORTANT NOTE
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges
are to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice,
cheque or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to
ensure all details are as published. IBC assumes no further
liability or obligation, beyond the refund of the paid registration
fee, in the event of postponement or cancellation by IBC.
DATA PROTECTION
REG NO. 200108203N
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry date, registration
and payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure
portal built into the website. To pay by phone please indicate
the contact name and details below and our Customer
Services Team will call within 24 hours to take payment.
Please do not send credit card information by email.
The personal information entered during your registration/order,
or provided by you, will be held on a database and may be
shared with companies in the Informa Group in the UK and
internationally. Occasionally, your details may be obtained from
or shared with external companies who wish to communicate
with you offers related to your business activities. If you do not
wish your details to be used for this purpose, please contact our
Database Department at Email: database@ibcasia.com.sg,
Tel: +65 6508 2400 or Fax: +65 6508 2408.
6 EASY WAYS TO REGISTER
RESERVE YOUR PLACE TODAY!
■ Yes! I/We will attend the Oncology Asia, 25 – 28 November 2014, PARKROYAL on Beach Road, Singapore
■ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 3 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 4 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Main Business/Activity:
Postal Code:
Please photocopy for additional delegates
■ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
■ I am paying by bank transfer (copy attached)
■ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
PAYMENT METHOD
(Please tick)
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.oncologyasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name
and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the
strictest confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46255
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.oncologyasia.com